title: Neurotoxicity of antitumoral IL-2 therapy: evoked cognitive potentials and brain mapping.
abstract: Antitumoral interleukin-2 (IL-2) therapy is frequently associated with a neurotoxicity that manifests itself in neuropsychiatric disturbances and, more rarely, with neurological focal signs. With the aim of documenting the involvement of cognitive functions after IL-2 treatment, we studied 20 patients using evoked cognitive potentials (P300) and computer analysis of the EEG signal. A comparison of the tests performed before and after the subcutaneous infusion of IL-2 showed a significant lengthening in mean P300 latencies and a percentage increase in the EEG frequencies contained with the delta and theta bands, especially in the frontal regions.
authors.affiliation: Servizio di Neurologia, Istituto Regina Elena per lo Studio e la Cura di Tumori, Roma.
authors.forename: A
authors.initials: A
authors.lastname: Pace
authors.forename: A
authors.initials: A
authors.lastname: Pietrangeli
authors.forename: L
authors.initials: L
authors.lastname: Bove
authors.forename: M
authors.initials: M
authors.lastname: Rosselli
authors.forename: M
authors.initials: M
authors.lastname: Lopez
authors.forename: B
authors.initials: B
authors.lastname: Jandolo
mesh_terms: D000328:Adult; D000368:Aged; D001921:Brain / Q000502:physiology*; D001931:Brain Mapping; D004569:Electroencephalography / Q000187:drug effects; D005074:Evoked Potentials, Visual / Q000187:drug effects*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology
chemical_list: D007376:Interleukin-2